Evidence map›Paper›PMID 35693709›Full record

ArticleTranslational andrology and urology2022

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients.

Aihetaimujiang Anwaier, Jianhui Chen, Hongfeng Zhou, Xinxin Zhao, Song Zheng, Xiaofan Li, Yuanyuan Qu, Guohai Shi, Hailiang Zhang, Jin Wu and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Aihetaimujiang Anwaier *Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianhui Chen *Department of Urology, Fujian Medical University Union Hospital, Fuzhou, China.
Hongfeng Zhou *Department of Head and Neck and Genito-Urinary Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Xinxin ZhaoDepartment of Head and Neck and Genito-Urinary Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Song ZhengDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, China.
Xiaofan LiDepartment of Hematology, Fujian Institute of Hematology Union Hospital, Fujian Medical University, Fuzhou, China.
Yuanyuan QuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Guohai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hailiang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jin WuDepartment of Head and Neck and Genito-Urinary Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Fudan University Shanghai Cancer Center · CNHarbin Medical University · CNFujian Medical University · CNUnion Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pazopanib was recommended as first-line treatment option for Metastatic renal cell carcinoma (mRCC), while evidence from strictly selected patients has poor external validity and clinical characteristics are complex in real-world clinical practice. This study aimed to illustrate the survival benefits and safety of pazopanib monotherapy using real-world data of mRCC patients. Methods: This was a retrospective, multicenter, cohort study. We recruited adult patients with International Metastatic renal cell carcinoma Database Consortium (IMDC) favorable- and intermediate-risk mRCC receiving first-line pazopanib from May 2017 to February 2020. Patients were treated with pazopanib 800 mg or 600 mg orally once daily. Treatment efficacy, and drug safety were analyzed. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Drug safety was assessed according to the grade of treatment-related adverse reactions. Results: Based on IMDC risk stratification, there were 46 (32.2%) patients in the favorable-risk group and 97 (67.8%) patients in the intermediate-risk group. The median progression-free survival (PFS) of the entire cohort, favorable- and intermediate risk groups was 21.2, 27.1 and 17.2 months, respectively. In the intermediate-risk group, PFS was much longer in patients with 1 risk factor than in patients with 2 risk factors, with a median of 25.9 months versus 11.2 months (P<0.0001). Patients with lung metastasis only had longer PFS than those with bone metastasis only, with a median PFS of 25.9 Conclusions: This real-world data analysis recommended that patients in intermediate-risk group need to be further stratified according to the number of risk factors. Pazopanib was most suitable for patients with lung metastasis only. Local treatment for metastatic lesions should only be recommended in IMDC favorable patients.

Indexed as

International Metastatic Renal Cell Carcinoma Database Consortium risk model (IMDC risk model)Metastatic renal cell carcinoma (mRCC)pazopanibreal-worldtargeted therapy

Identifiers

PMID35693709
PMCPMC9177258
OpenAlexW4282946349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.